Publikation:

Modeling of levothyroxine in newborns and infants with congenital hypothyroidism : challenges and opportunities of a rare disease multi-center study

Lade...
Vorschaubild

Dateien

Koch_2-16ixvgr1fs0704.pdf
Koch_2-16ixvgr1fs0704.pdfGröße: 884.26 KBDownloads: 222

Datum

2021

Autor:innen

Leroux, Stephanie
Gotta, Verena
Gächter, Pascal
Welzel, Tatjana
Janner, Marco
et al.

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

ArXiv-ID

Internationale Patentnummer

Link zur Lizenz

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Open Access Hybrid
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Journal of pharmacokinetics and pharmacodynamics. Springer. 2021, 48(5), pp. 711-723. ISSN 1567-567X. eISSN 1573-8744. Available under: doi: 10.1007/s10928-021-09765-w

Zusammenfassung

Modeling of retrospectively collected multi-center data of a rare disease in pediatrics is challenging because laboratory data can stem from several decades measured with different assays. Here we present a retrospective pharmacometrics (PMX) based data analysis of the rare disease congenital hypothyroidism (CH) in newborns and infants. Our overall aim is to develop a model that can be applied to optimize dosing in this pediatric patient population since suboptimal treatment of CH during the first 2 years of life is associated with a reduced intelligence quotient between 10 and 14 years. The first goal is to describe a retrospectively collected dataset consisting of 61 newborns and infants with CH up to 2 years of age. Overall, 505 measurements of free thyroxine (FT4) and 510 measurements of thyrotropin or thyroid-stimulating hormone were available from patients receiving substitution treatment with levothyroxine (LT4). The second goal is to introduce a scale/location-scale normalization method to merge available FT4 measurements since 34 different postnatal age- and assay-specific laboratory reference ranges were applied. This method takes into account the change of the distribution of FT4 values over time, i.e. a transformation from right-skewed towards normality during LT4 treatment. The third goal is to develop a practical and useful PMX model for LT4 treatment to characterize FT4 measurements, which is applicable within a clinical setting. In summary, a time-dependent normalization method and a practical PMX model are presented. Since there is no on-going or planned development of new pharmacological approaches for CH, PMX based modeling and simulation can be leveraged to personalize dosing with the goal to enhance longer-term neurological outcome in children with the rare disease CH.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
510 Mathematik

Schlagwörter

Normalization, Reference range, Scale/location-scale, Pediatrics, Pharmacokinetics, Levothyroxine, Congenital hypothyroidism, Rare disease, Thyroid

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690KOCH, Gilbert, Britta STEFFENS, Stephanie LEROUX, Verena GOTTA, Johannes SCHROPP, Pascal GÄCHTER, Freya BACHMANN, Tatjana WELZEL, Marco JANNER, 2021. Modeling of levothyroxine in newborns and infants with congenital hypothyroidism : challenges and opportunities of a rare disease multi-center study. In: Journal of pharmacokinetics and pharmacodynamics. Springer. 2021, 48(5), pp. 711-723. ISSN 1567-567X. eISSN 1573-8744. Available under: doi: 10.1007/s10928-021-09765-w
BibTex
@article{Koch2021-10Model-54279,
  year={2021},
  doi={10.1007/s10928-021-09765-w},
  title={Modeling of levothyroxine in newborns and infants with congenital hypothyroidism : challenges and opportunities of a rare disease multi-center study},
  number={5},
  volume={48},
  issn={1567-567X},
  journal={Journal of pharmacokinetics and pharmacodynamics},
  pages={711--723},
  author={Koch, Gilbert and Steffens, Britta and Leroux, Stephanie and Gotta, Verena and Schropp, Johannes and Gächter, Pascal and Bachmann, Freya and Welzel, Tatjana and Janner, Marco}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/54279">
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Bachmann, Freya</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-07-12T12:44:59Z</dcterms:available>
    <dc:contributor>Leroux, Stephanie</dc:contributor>
    <dc:contributor>Schropp, Johannes</dc:contributor>
    <dc:contributor>Koch, Gilbert</dc:contributor>
    <dcterms:abstract xml:lang="eng">Modeling of retrospectively collected multi-center data of a rare disease in pediatrics is challenging because laboratory data can stem from several decades measured with different assays. Here we present a retrospective pharmacometrics (PMX) based data analysis of the rare disease congenital hypothyroidism (CH) in newborns and infants. Our overall aim is to develop a model that can be applied to optimize dosing in this pediatric patient population since suboptimal treatment of CH during the first 2 years of life is associated with a reduced intelligence quotient between 10 and 14 years. The first goal is to describe a retrospectively collected dataset consisting of 61 newborns and infants with CH up to 2 years of age. Overall, 505 measurements of free thyroxine (FT4) and 510 measurements of thyrotropin or thyroid-stimulating hormone were available from patients receiving substitution treatment with levothyroxine (LT4). The second goal is to introduce a scale/location-scale normalization method to merge available FT4 measurements since 34 different postnatal age- and assay-specific laboratory reference ranges were applied. This method takes into account the change of the distribution of FT4 values over time, i.e. a transformation from right-skewed towards normality during LT4 treatment. The third goal is to develop a practical and useful PMX model for LT4 treatment to characterize FT4 measurements, which is applicable within a clinical setting. In summary, a time-dependent normalization method and a practical PMX model are presented. Since there is no on-going or planned development of new pharmacological approaches for CH, PMX based modeling and simulation can be leveraged to personalize dosing with the goal to enhance longer-term neurological outcome in children with the rare disease CH.</dcterms:abstract>
    <dc:creator>Gotta, Verena</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:contributor>Steffens, Britta</dc:contributor>
    <dc:language>eng</dc:language>
    <dcterms:issued>2021-10</dcterms:issued>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/54279/1/Koch_2-16ixvgr1fs0704.pdf"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/54279"/>
    <dc:creator>Janner, Marco</dc:creator>
    <dc:creator>Koch, Gilbert</dc:creator>
    <dc:creator>Schropp, Johannes</dc:creator>
    <dc:contributor>Gotta, Verena</dc:contributor>
    <dc:contributor>Gächter, Pascal</dc:contributor>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <dc:contributor>Bachmann, Freya</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-07-12T12:44:59Z</dc:date>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/54279/1/Koch_2-16ixvgr1fs0704.pdf"/>
    <dc:creator>Leroux, Stephanie</dc:creator>
    <dc:creator>Gächter, Pascal</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/39"/>
    <dc:contributor>Welzel, Tatjana</dc:contributor>
    <dc:creator>Welzel, Tatjana</dc:creator>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/39"/>
    <dcterms:title>Modeling of levothyroxine in newborns and infants with congenital hypothyroidism : challenges and opportunities of a rare disease multi-center study</dcterms:title>
    <dc:contributor>Janner, Marco</dc:contributor>
    <dc:creator>Steffens, Britta</dc:creator>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen